There may be other available opportunities that are similar to this investment but have different attributes, characteristics, cost factors, and fees. 
 Disclosures & Disclaimers

iRemedy addresses serious industry problems by creating a large and powerful procurement marketplace — powered by our groundbreaking AI technology.  

We help doctors, hospitals and healthcare providers get lifesaving supplies for their patients faster and more affordably.

---

🎉 Transparent pricing   
We keep prices transparent so providers can find the best deal right away and get supplies faster. Full transparency means everyone knows the price right away.

🛒 Easy ordering
Simple, fast, and secure. Our B2B and B2C systems are state-of-the-art, user-friendly and direct — what you see is what you get. No more faxes, confusing order forms, or hours on hold with sales reps.

🤖 Constant supply monitoring 
iRemedy uses groundbreaking AI to track inventory, shipments, and manufacturers 24/7. Customers can easily stay aware of shortages and manage solutions, so they don’t waste valuable time and money.

The medical supply industry is broken — that’s why we decided to fix it.

By pairing modern technology buying experiences and people led customer service with AI we’re poised to make a big impact on the medical supply industry. In 2022 we did $52M in revenue — and for good reason.

Our mission is to build the largest and smartest medical supply catalog in the world. We are designing AI technologies to learn everything about the complex, global medical supply chain to better manage getting products to our customers. 

To achieve this, we developed a differentiated AI approach called para-intelligence for healthcare applications at iRemedy. It allows users & AI machines to collaborate in the coming era of human-digital workforces, starting with healthcare supply chains, the most underserved sector of an underserved industry.

Our mission is to solve complex pricing, contracting, and sourcing problems – automatically. 

$52M in 2022 revenue

In 2022, we exceeded $52M in revenue.

Over 10K customers served

iRemedy has already served over 10,000 customers, ranging from at home consumers to large, multi-location medical clinics, hospitals, government agencies and NGO's.

---

Reviews Independently Gathered and Reported by ShopperApproved.com

---

iRemedy has provide technology and products to a wide range of clients including government agencies, hospitals, NGO's, surgery centers, product companies and other healthcare providers.  A sampling of our customers includes Kimberly-Clark, Mayo Clinic, Trinity Health, Johns Hopkins Medicine, Brigham Young University, the American Red Cross, Banner Health, Johnson and Johnson, GE HealthCare, Baptist Health Care, New York Presbyterian, Pan Atlantic Health Organization, Celebration Pediatrics, National Ambulatory Surgery Center, Dental Safari, Washington State University and Boston University.

A better solution for a modern world

Medical supply purchasing has become unnecessarily complex and unreliable.  

For consumers at home and professionals at work, a more modern, intelligent, and friendly solution is needed. 

iRemedy delivers on that promise.

The medical supplies market is projected to reach $163.5B by 2027 from $138.4B in 2022, at a CAGR of 3.4% during the forecast period.¹

(1) MarketsandMarkets

Why are we so special?

Today's global supply chain problems require a modern solution.

iRemedy was born into a world that conquers complex problems with state-of-the-art, machine learning, computer automation and AI-driven technology.  

Our mission is to build the largest, smartest, publicly available medical supply catalog in the world.  

We solve complex shortage, pricing, contracting, and sourcing problems — by applying modern tech solutions.  

We are tomorrow's promise. 

Every American has experienced the pain caused by rising healthcare costs.  A big part of that is the unnecessarily high cost of supplies. 

Through our decades of work in the healthcare industry, and especially through the recent pandemic, we're alarmed at the rampant supply shortages and, in our view, unfair pricing, that is common in the medical supply industry.

Our team has designed some of the world's leading marketplace technologies and we put that experience to work to solve the supply chain problems that risk American lives.

To achieve this, we developed a differentiated AI approach called para-intelligence for healthcare applications at iRemedy.  It allows users & AI machines to collaborate in the coming era of human-digital workforces, starting with healthcare supply chains, the most underserved sector of an underserved industry.

Our growth and adoption have been rapid and fast growing. Thousands of users of all sizes and types from local physicians to the United States Government have relied on us to deliver their supplies.

In 2022, we generated over $52M in sales; and we expect our high growth to continue through 2023 and beyond.

In 2023, we expect rapid, 3X growth in both the ambulatory surgery center and multi-location ambulatory care markets. We also expect our government, large system and consumer markets to experience growth as we enhance our AI technology and build the breadth and 'intelligence' of our catalog offering. 

We employ solid corporate governance led by a team of experienced professionals, have several years of independently audited financials, and have had IPO negotiations with multiple investment banking firms as we explore exit opportunities for our investors.

The iRemedy team, leadership and Board of Directors, with the full support of our shareholders, is committed to delivering meaningful impact on our local and global communities.

Environmental

iRemedy is an industry leader working to advance the domestication of medical supply manufacturing. Currently, most medical supplies are manufactured overseas, mostly in China. Thousands of containers cross the oceans every day — making a vast contribution to the global carbon footprint. To counter this, we are actively involved in promoting, and supporting, the bourgeoning U.S. based medical manufacturing industry.

Democratization of Healthcare

Our mission is to make a greater selection of medical products, available to a wider audience, with more transparent pricing than has ever happened before. We believe that all healthcare providers, and all consumers, should have equal availability and fair pricing for the products they need to protect, restore and enhance their wellbeing.

Over $17.8M raised
in initial funding

from accredited investors,
including many healthcare professionals.

Experienced senior leadership

Combining healthcare, finance and
technology expertise to rapidly scale.

Tony Paquin 
Co-Founder, Chairman and CEO

• Two previous successful exits.
• Noted healthcare consultant and author.
• Founder and CEO, Agency One a leading insurance industry software company, later acquired by CNA Insurance.
• Founder and CEO, Medinex, an EMR solution — subsequently listed on the Nasdaq in a successful public offering.
• Co-inventor on 12 pending and issued patents.

Jim Harding
Chief Technology Officer

• As VP of Technology at Amazon, Jim was personally tasked by Jeff Bezos to build the "everything store".  Jim devised, architected, managed and launched what became the largest, most successful, marketplace in the world.
• At iRemedy, Jim and Tony have developed a differentiated AI approach called para-intelligence for healthcare applications at iRemedy.  It allows users & AI machines to collaborate in the coming era of human-digital workforces, starting with healthcare supply chains, the most underserved sector of an underserved industry. 

The time for change is now.

There’s never been a better time to empower patients and healthcare providers with a service that will not only make their lives easier but may save lives. 

When you invest in iRemedy, you’re investing in the future of healthcare — an industry desperate for revolutionary modernization. 

Don’t miss your chance to be a part of this incredible technology-fueled step forward.  Please join our growing community of investors today!

Risks of early stage investment. Not an offer to buy or sell securities. This is a long-term speculative illiquid investment. Investment is not FDIC or SiPC insured. You may lose money.

Your investment is binding and irrevocable, although we reserve the right to reject it for any reason or no reason at all. Funds committed will remain in an escrow account maintained by BankProv until such time as a closing occurs. We will not be issuing share certificates; your investment will be solely recorded in book-entry electronic form by Prolific Labs Incorporated (doing business as Pulley), our transfer agent. Securities offered through OpenDeal Broker LLC, a registered broker dealer, member of FINRA (www.finra.org), member of SIPC (www.sipc.org). We will pay OpenDeal Broker LLC, a registered broker-dealer, a cash commission equal to 5% of the amount raised through the Republic Platform and a securities commission equal to 2% of the dollar value of the securities issued to investors through the Republic Platform at the time of closing, plus certain offering costs. Please review OpenDeal Broker LLC’s Form CRS. OpenDeal Broker LLC may require additional documents or information from you to complete your purchase, you will be contacted by a registered representative in this event.

An offering statement relating to The iRemedy Healthcare Companies, Inc.’s Common Stock has been filed with the Securities and Exchange Commission and became qualified on February 13, 2023. Prior to making any investment in The iRemedy Healthcare Companies, Inc.’s Common Stock, you should review a copy of the offering circular or contact The iRemedy Healthcare Companies, Inc. by phone at (407) 395-4283. No offer to sell any securities, and no solicitation of an offer to buy any securities, is being made in any jurisdiction in which such offer, sale, or solicitation would not be permitted by applicable law.